Cumberland Pharmaceuticals Inc. (CPIX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 39.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $39.90M | (m) | (m) |
| 2026-03-31 | (m) | $41.94M | $7.18M | (m) |
| 2025-12-31 | (m) | $44.52M | $6.67M | (m) |
| 2025-09-30 | (m) | $41.28M | $6.40M | (m) |
| 2025-06-30 | (m) | $42.07M | $6.74M | (m) |
| 2025-03-31 | (m) | $41.08M | $6.44M | (m) |
| 2024-12-31 | (m) | $37.87M | $6.59M | (m) |
| 2024-09-30 | (m) | $36.79M | $6.14M | (m) |
| 2024-06-30 | (m) | $37.79M | $6.58M | (m) |
| 2024-03-31 | (m) | $38.83M | $6.39M | (m) |
| 2023-12-31 | (m) | $39.55M | $6.07M | (m) |
| 2023-09-30 | (m) | $37.99M | $7.19M | (m) |
| 2023-06-30 | (m) | $39.32M | $7.65M | (m) |
| 2023-03-31 | (m) | $38.73M | $8.16M | (m) |
| 2022-12-31 | (m) | $40.68M | $9.12M | (m) |
| 2022-09-30 | (m) | $40.27M | $9.79M | (m) |
| 2022-06-30 | (m) | $36.93M | $8.90M | (m) |
| 2022-03-31 | (m) | $35.68M | $8.61M | (m) |
| 2021-12-31 | (m) | $35.05M | $8.81M | (m) |
| 2021-09-30 | (m) | $36.33M | $7.75M | (m) |
| 2021-06-30 | (m) | $37.50M | $8.57M | (m) |
| 2021-03-31 | (m) | $38.05M | $9.44M | (m) |
| 2020-12-31 | (m) | $35.84M | $8.65M | (m) |
| 2020-09-30 | (m) | $47.65M | $10.11M | (m) |
| 2020-06-30 | (m) | $45.33M | $9.55M | (m) |
| 2020-03-31 | (m) | $45.15M | $8.73M | (m) |
| 2019-12-31 | (m) | $45.55M | $8.75M | (m) |
| 2019-09-30 | (m) | $46.81M | $8.80M | (m) |
| 2019-06-30 | (m) | $44.93M | $8.34M | (m) |
| 2019-03-31 | (m) | $43.52M | $7.85M | (m) |
| 2018-12-31 | (m) | $40.20M | $7.38M | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $35.73M | (m) | (m) |
| 2014-06-30 | (m) | $32.53M | (m) | (m) |
| 2014-03-31 | (m) | $29.86M | (m) | (m) |
| 2013-12-31 | (m) | $32.03M | (m) | (m) |
| 2013-09-30 | (m) | $37.56M | (m) | (m) |
| 2013-06-30 | (m) | $43.57M | (m) | (m) |
| 2013-03-31 | (m) | $48.85M | (m) | (m) |
| 2012-12-31 | (m) | $48.85M | (m) | (m) |
| 2012-09-30 | (m) | $48.19M | (m) | (m) |
| 2012-06-30 | (m) | $48.71M | (m) | (m) |
| 2012-03-31 | (m) | $50.73M | (m) | (m) |
| 2011-12-31 | (m) | $51.14M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $45.88M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $43.54M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |